Ibogaine in the US: Legal Status and What's Coming (2026)
Ibogaine is a Schedule I substance with zero legal therapeutic access anywhere in the US, so Americans travel abroad for treatment. But Colorado is weighing first-in-the-nation regulated access, and Texas and Mississippi have funded major clinical trials. A verified, regularly updated tracker — with a plain-English cardiac safety warning and the decriminalized-vs-regulated distinction most pages get wrong.
Eric Bryant
Updated Jul 14, 2026 · Originally published Jul 14, 2026 · 19 min read
The Psychedelic Beacon Team researches and writes educational content about ketamine and psychedelic-assisted therapies to help patients make informed decisions.
Ibogaine occupies a strange position in American drug policy: intensely promising, intensely dangerous, and — for now — completely off-limits. It is a Schedule I controlled substance, which means that as far as the federal government is concerned it has no accepted medical use, and there is no legal way to receive ibogaine treatment anywhere in the United States. Yet two of the largest state-funded psychedelic research programs in the country are now aimed squarely at it, and Colorado is deciding whether to become the first jurisdiction in the world to offer it as a regulated, supervised therapy.
This tracker lays out exactly where ibogaine stands: its federal status, Colorado's first-in-the-nation decision and the sourcing problem hanging over it, the research wave in Texas and Mississippi, what the evidence does and does not support, and — prominently, because it is the single most important thing to understand about this drug — its cardiac risk. Every factual claim links to its primary source. Updated July 14, 2026.
Track ibogaine's legal status
Ibogaine has no legal treatment access in the US today — but Colorado's regulated-access decision and the Texas and Mississippi trials could change that. Tell us your state and we'll email you when there's real news. A few emails a year, only when something material changes.
⚠️ Cardiac safety: read this first
Ibogaine can cause fatal heart-rhythm disturbances. It and its long-lived metabolite noribogaine block a specific cardiac potassium channel (hERG/IKr), which prolongs the heart's QT interval and can trigger a dangerous arrhythmia called torsades de pointes, ventricular fibrillation, and cardiac arrest. These events have occurred at therapeutic doses, in people with no known prior heart disease, and can strike hours or even days after a dose because of the slow-clearing metabolite.
This is not a hypothetical. It is the reason ibogaine is so tightly restricted, the reason unsupervised use abroad has killed people, and the reason every serious research protocol screens the heart before dosing and monitors it throughout. The safety section below has the details and the sources.
Latest Updates
- July 1, 2026 — Mississippi's Ibogaine Drug Development Clinical Trial Act (HB 314) takes effect, authorizing the State Department of Health to select a consortium to run an FDA drug-development trial. It was approved by Governor Tate Reeves on March 26, 2026.
- June 4, 2026 — Colorado Governor Jared Polis signs HB26-1325, creating an ibogaine research pilot program in the Behavioral Health Administration (effective August 12, 2026). This is a research pilot — it does not by itself add ibogaine to the state's regulated healing-center program.
- March 31, 2026 — Texas announces it will run its own ibogaine trials after private drug-company partners declined the state's terms, the Texas Tribune reported. The $50 million program under SB 2308 proceeds through a public-university consortium (Texas Tribune).
- February 3, 2026 — Axios Denver reports that Colorado's spring rules review will formally consider adding ibogaine, which would make it the first state to license the substance for regulated treatment (Axios Denver).
- December 12, 2025 — UTMB Health and UTHealth Houston are awarded $50 million by Texas to lead the IMPACT consortium's ibogaine clinical trials.
- September 2025 — Colorado's Natural Medicine Advisory Board votes 5–2 to recommend therapeutic access to ibogaine, as Westword reported. The recommendation now awaits sign-off from two state agency directors.
Current Status: Schedule I, Zero Legal Access
Ibogaine is a Schedule I controlled substance under the federal Controlled Substances Act, listed at 21 CFR § 1308.11 (DEA drug code 7260) as a constituent of the plant Tabernanthe iboga. Schedule I is the most restrictive tier, reserved for substances the government treats as having a high potential for abuse and no currently accepted medical use in the United States. It has held that status since the modern federal drug schedules were created in 1970.
The practical consequence is stark: there is no legal way to receive ibogaine treatment anywhere in the US. No state has a licensed ibogaine provider. No clinic can lawfully administer it outside of research authorized by the FDA. This is true regardless of what any individual state has done on decriminalization — federal Schedule I status applies everywhere.
Because of that, Americans who seek ibogaine treatment travel abroad, most often to clinics in Mexico, where the substance is unregulated, and to Costa Rica and other countries. This was the pathway used even by the veterans in the most-cited US research: a 2024 Stanford Medicine study followed 30 special-operations veterans who independently arranged treatment at a clinic in Mexico, because there was no legal option at home. These offshore clinics operate outside US medical oversight, and their screening, dosing, and cardiac-monitoring standards vary widely — which, given the cardiac risk described below, is a serious concern.
The Colorado Decision: Closer Than Anywhere Else on Earth
Colorado is the only place in the country seriously moving toward regulated ibogaine access — and it is important to separate that from the state's existing decriminalization, which does not provide any legal way to obtain the drug (more on that distinction below).
The regulated pathway runs through Colorado's Natural Medicine Health Act (SB23-290), which built a licensed, supervised program that today covers only psilocybin and psilocyn. That law allows the state's Natural Medicine Advisory Board to recommend adding three additional substances — DMT, ibogaine, and mescaline (excluding peyote) — on or after June 1, 2026.
The board moved first on ibogaine. In September 2025, the Natural Medicine Advisory Board voted 5–2 to recommend therapeutic access to ibogaine, as Westword reported (the vote was also covered by Marijuana Moment). Crucially, the recommendation is a recommendation, not a decision. It now goes to the executive directors of two state agencies — the Department of Revenue (DOR), whose director serves as the State Licensing Authority and is the final decision-maker on natural-medicine rules, and the Department of Regulatory Agencies (DORA). As Axios Denver reported, "two state agencies must sign off," and Colorado's rules review formally taking up ibogaine began in spring 2026.
As of mid-July 2026, that sign-off has not happened and ibogaine has not been added to the regulated program. The state's Natural Medicine Division rulemaking page shows spring 2026 rulemaking proceedings underway, with the State Licensing Authority identified as the final decision-maker; no rule adding ibogaine to licensed healing centers has been adopted. If and when it is, Colorado would become the first jurisdiction in the world to license supervised ibogaine treatment — Axios framed the change as making Colorado "the first state in the country" to use ibogaine for regulated medical treatment.
The Nagoya Protocol Sourcing Obstacle
The biggest thing standing between the board's recommendation and an actual licensed program is not politics — it is supply. Ibogaine comes from the root bark of the iboga shrub, native to Central Africa, and the plant's ceremonial use is culturally and legally protected in Gabon. The board's recommendation is explicitly conditioned on compliance with the Nagoya Protocol, an international agreement on the fair and equitable sharing of benefits from genetic resources and traditional knowledge.
The problem: the United States is not a party to the Nagoya Protocol, which complicates lawful importation. At its August 14, 2025 meeting, the board recommended that the state "write a letter of intent to start and follow Nagoya Protocol" and "request a waiver to the Controlled Substance Act from the Federal Government to import Iboga or Ibogaine extract/powder from existing Gabon infrastructure that is Nagoya protocol compliant," per the Colorado Natural Medicine News page. An alternative floated in the board's discussions, as Westword noted, is to cultivate iboga in the US while still engaging in benefit-sharing with the people of Gabon. Either path is unresolved, and it is the single largest practical question mark over Colorado's timeline.
A Separate Research Pilot: HB26-1325
Running alongside the regulated-access question, Colorado also created a research track. On June 4, 2026, Governor Polis signed HB26-1325, which establishes an ibogaine research pilot program within the state's Behavioral Health Administration (effective August 12, 2026). Per the bill summary, it authorizes up to five pilot sites to study ibogaine for mental-health conditions and substance use disorders, directs the licensing authority to adopt rules for ibogaine's administration and manufacturing, and requires any ibogaine licensee to establish a benefit-sharing plan with Indigenous communities. Notably, the pilot is funded through gifts, grants, and donations rather than state appropriations, so it is contingent on outside money — a point Westword emphasized in its coverage of the signing.
The pilot and the regulated-access recommendation are two distinct tracks. The pilot is research; the advisory-board recommendation, if the agency directors adopt it, would be the thing that actually lets a licensed healing center offer ibogaine to the public. Neither has produced legal patient access yet.
The Research Wave: Texas, Mississippi, and Veterans
While Colorado works the regulatory angle, two states have put serious public money into the parallel goal of getting ibogaine through the FDA as an approved medicine.
Texas: A $50 Million Consortium
Texas has made the largest state bet. Under SB 2308, signed by Governor Greg Abbott in 2025, the state committed $50 million to ibogaine drug-development trials aimed at FDA approval for opioid use disorder and other conditions. In December 2025, UTMB Health and UTHealth Houston were awarded the funding to lead the IMPACT consortium — Ibogaine Medicine for PTSD, Addiction, and Cognitive Trauma — a two-year, multicenter effort that also includes Texas Tech, the University of Texas at Austin, Baylor College of Medicine, and other Texas institutions. One branch focuses on interrupting opioid use disorder; another concentrates on traumatic brain injury and PTSD, especially in veterans.
The program hit a snag. As the Texas Tribune reported on March 31, 2026, the state's original plan required a private drug-company partner to match the $50 million and commit a share of future revenue — terms the companies rejected as too demanding for such a high-risk area. Texas responded by announcing it would proceed with its own university-led research program instead. The Tribune noted this may require legislative fixes, since SB 2308 as written contemplates private matching funds.
Mississippi: HB 314
Mississippi followed with the Ibogaine Drug Development Clinical Trial Act (HB 314), which was approved by Governor Tate Reeves on March 26, 2026 and takes effect July 1, 2026, per the official bill history. The act authorizes the State Department of Health to select a consortium — which must be anchored by a university or hospital — to conduct an FDA drug-development trial with the explicit goal of securing FDA approval of ibogaine for opioid use disorder, co-occurring substance use disorder, and other conditions. Like Texas, it requires the consortium to secure matching funds from non-state sources before money is disbursed, and it directs the Mississippi effort to coordinate with the lead consortium in another state that has filed an Investigational New Drug application with the FDA.
The Veterans and TBI Angle
Much of the political momentum behind these programs comes from veterans. The most-cited US evidence is the 2024 Stanford Medicine study led by Dr. Nolan Williams, which followed 30 special-operations veterans with histories of traumatic brain injury who received ibogaine — combined with magnesium, specifically to reduce cardiac risk — at a clinic in Mexico. One month after treatment, participants reported large improvements: the researchers described roughly an 88% reduction in PTSD symptoms, 87% in depression, and 81% in anxiety, alongside sharply lower disability ratings. Those are striking numbers, and they explain the enthusiasm — but as the section below stresses, the study design was observational, without a control group, and with only short follow-up.
What Ibogaine Is Used to Treat — and How Strong the Evidence Really Is
It is easy to find dramatic claims about ibogaine. It is harder, and more honest, to separate what is genuinely promising from what has actually been proven. Here is the conservative read:
- Opioid and other substance use disorders — This is the strongest area of interest. Observational studies and case series report that a single ibogaine session can sharply reduce opioid withdrawal and craving, sometimes for weeks or months. This is why both Texas and Mississippi aimed their trials here. But the underlying evidence is largely uncontrolled, and no ibogaine product has completed the randomized controlled trials the FDA requires.
- Traumatic brain injury and PTSD (veterans) — The 2024 Stanford observational study reported large improvements in trauma-related symptoms, but with no control group and a one-month follow-up window. It is a promising signal, not proof of efficacy.
- Depression and anxiety — Improvements are frequently reported alongside the above, but again from uncontrolled settings and often entangled with the treatment of the primary condition.
The honest bottom line: ibogaine has not been proven effective for any condition by the standard the FDA uses to approve medicines. The entire point of the Texas, Mississippi, and Colorado research programs is to generate the controlled data that does not yet exist. Anyone presenting ibogaine as an established cure is getting ahead of the evidence.
The Cardiac Risk: In Detail
The reason ibogaine is not simply "the promising addiction drug nobody will approve" is its heart toxicity, which is real, mechanistic, and sometimes fatal.
Ibogaine and its principal metabolite, noribogaine, block the cardiac hERG potassium channel that carries the rapid delayed-rectifier current (IKr) responsible for the heart's electrical recovery between beats. Blocking it reduces the heart's "repolarization reserve," which prolongs the QT interval and can precipitate torsades de pointes — a life-threatening ventricular arrhythmia — as well as ventricular tachycardia, ventricular fibrillation, and cardiac arrest. This mechanism and its consequences are laid out in a 2026 scoping review of ibogaine cardiac safety in the peer-reviewed literature.
Several features make the risk especially treacherous:
- It occurs at therapeutic doses, in apparently healthy people. Documented cases of severe QT prolongation and arrhythmia have happened in individuals without known pre-existing cardiac disease — this is not solely a story about overdose or hidden heart conditions.
- It can be delayed. Because noribogaine clears slowly, dangerous rhythm disturbances can appear many hours, and in some reports even days, after the dose — well after a person might assume the acute experience is over. A published case report of cardiac arrest after ibogaine documents this pattern.
- Individual metabolism varies. People metabolize ibogaine differently depending on their CYP2D6 enzyme activity, so a "normal" dose can behave very differently from person to person.
Historically, before modern screening protocols, mortality estimates from ibogaine treatment ran on the order of roughly 1 death per several hundred treatments — the frequently cited figure of about 1 in 427 was derived from cases between 1989 and 2006, per the scoping review. Contemporary research protocols are specifically designed to mitigate this: baseline ECG and cardiac screening, exclusion of people with QT-prolonging conditions or medications, continuous cardiac monitoring during and after dosing, and — as in the Stanford veterans protocol — co-administration of magnesium to buffer the QT effect. None of that mitigation exists at an unscreened underground or offshore session, which is precisely why the setting matters so much.
This is the crux of the regulatory tension: ibogaine's therapeutic promise and its cardiac danger are inseparable, and the whole purpose of a regulated program — as opposed to decriminalized personal use — is to put the medical guardrails in place.
Decriminalized Is Not the Same as Legal Access
Almost every page you will read about ibogaine and Colorado blurs two completely different things. Getting this right is the most important takeaway on this page.
Decriminalization removes or reduces state criminal penalties for personal conduct. Under Colorado's Proposition 122 (the Natural Medicine Health Act, 2022), adults 21 and older will not face state criminal charges for personal possession, use, or cultivation of five natural psychedelics, including ibogaine. That is a real change — but it is only the removal of a penalty.
Regulated access is an entirely separate thing: a licensed, supervised system with approved providers, a legal supply chain, safety screening, and a place you can actually go to receive treatment. Colorado has that system for psilocybin. It does not have it for ibogaine. No licensed ibogaine provider exists. There is no legal supply. There is no lawful place to obtain a supervised ibogaine session.
So the accurate statement is: in Colorado, ibogaine is decriminalized for personal use but there is no legal, regulated way to access it as a treatment — and it remains federally illegal everywhere as a Schedule I substance. The whole significance of the advisory board's 2025 recommendation is that it could, for the first time, turn decriminalized-but-inaccessible into genuinely, legally available under medical supervision. Until the agency directors sign off and rules are written, that has not happened. Any page telling you that you can "legally get ibogaine treatment in Colorado" is conflating these two ideas and is simply wrong.
Frequently Asked Questions
Is ibogaine legal in the United States?
No. Ibogaine is a Schedule I controlled substance under federal law — the most restrictive category, reserved for substances treated as having no currently accepted medical use. There is no legal way to receive ibogaine treatment anywhere in the US as of July 2026. The only lawful use is inside FDA-authorized clinical research.
Isn't ibogaine decriminalized in Colorado?
Personal possession and use by adults 21+ is decriminalized in Colorado under Proposition 122, which removed state criminal penalties. But decriminalization is not legal, regulated access: there are no licensed providers, no legal supply, and no place to obtain a supervised session — and ibogaine remains federally illegal regardless. Colorado is separately weighing whether to add ibogaine to its regulated Natural Medicine program, but that decision has not been made.
Where do Americans go for ibogaine treatment?
Because there is no legal US access, Americans travel abroad — most commonly to clinics in Mexico, where ibogaine is unregulated, and to Costa Rica and elsewhere. These clinics operate outside US medical oversight, and screening and cardiac-monitoring standards vary widely. Given ibogaine's documented risk of fatal heart arrhythmia, medical screening and monitoring are not optional details.
What is ibogaine used to treat?
The strongest interest is in opioid and other substance use disorders, and in trauma-related conditions such as PTSD and traumatic brain injury in veterans. The evidence so far is mostly observational, not the large randomized controlled trials the FDA requires. No use of ibogaine has been proven to FDA standards.
Could Colorado really be first in the world?
Potentially. Colorado's Natural Medicine Advisory Board voted in September 2025 to recommend adding ibogaine to the regulated program. If the two agency directors sign off and rulemaking is completed, Colorado would be the first jurisdiction anywhere to license supervised ibogaine treatment. The chief obstacle is sourcing the plant in compliance with the international Nagoya Protocol.
Get ibogaine updates when they're real
We'll email you when there's genuine news on ibogaine's legal status — Colorado's decision, the Texas and Mississippi trials, and any first legal treatment access. Tell us your state. A few emails a year, only when something material changes.
Related Reading
- Psilocybin Therapy Legal States (2026) — the full state-by-state breakdown, including Colorado's Natural Medicine program that ibogaine may join.
- Psilocybin FDA Approval Status Tracker — how the closest-to-approval psychedelic is moving through the FDA, the pathway ibogaine's trials are ultimately aiming for.
Sources
- eCFR: 21 CFR § 1308.11 — Schedule I (ibogaine, DEA code 7260, constituent of Tabernanthe iboga)
- Colorado General Assembly: SB23-290 — Natural Medicine Regulation and Legalization (Natural Medicine Health Act)
- Colorado General Assembly: HB26-1325 — Natural Medicine (ibogaine research pilot program)
- Colorado Department of Revenue, Natural Medicine Division: Rulemaking (spring 2026 proceedings; State Licensing Authority as final decision-maker)
- Colorado Division of Professions and Occupations: Natural Medicine News (August 14, 2025 board recommendation on Nagoya Protocol and CSA import waiver)
- Westword: Colorado Natural Medicine Board Recommends Ibogaine for Therapeutic Use (Brendan Joel Kelley, September 2025; 5–2 vote, sourcing)
- Westword: Colorado's New Ibogaine Law (Brendan Joel Kelley, June 11, 2026; HB26-1325 signing and funding contingency)
- Marijuana Moment: Colorado Psychedelics Board Votes To Recommend Adding Ibogaine To Regulated Healing Centers (Kyle Jaeger, September 2025)
- Axios Denver: Colorado Psychedelic Therapy Program Considers Expanding Options (Esteban L. Hernandez, February 3, 2026; two-agency sign-off, first-in-nation framing)
- Texas Legislature: SB 2308 (89th Legislature) (ibogaine drug-development trials)
- UTMB Health: UTMB and UTHealth Houston Awarded $50 Million to Lead Ibogaine Clinical Trials (December 12, 2025; IMPACT consortium)
- Texas Tribune: Texas to Conduct Its Own Ibogaine Clinical Trials (Stephen Simpson and Alex Nguyen, March 31, 2026)
- Mississippi Legislature: HB 314 — Ibogaine Drug Development Clinical Trial Act (as signed) and bill history (approved by Governor March 26, 2026; effective July 1, 2026)
- Stanford Medicine: Ibogaine Treatment Associated with Improvements in Veterans with Traumatic Brain Injury (Nolan Williams; observational study of 30 special-operations veterans)
- PMC / peer-reviewed scoping review: Ibogaine: Therapeutic Potential, Cardiac Safety, and Translational Perspectives (hERG/IKr mechanism, QT prolongation, historical mortality estimate)
- PMC / Journal of Arrhythmia: Cardiac Arrest After Ibogaine Intoxication (delayed arrhythmia case report)
This article is for informational purposes only and does not constitute medical advice. Ibogaine carries a serious risk of fatal cardiac arrhythmia and is a Schedule I controlled substance; it is not legally available for treatment in the United States. Consult a qualified healthcare provider before making any treatment decisions.
Related articles
Ready to find a provider?
Psychedelic Beacon is a directory, not a marketplace. We verify licensure against public registries where we can and mark self-reported claims where we can’t.